Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 4/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046532 | 1.00 | PTGIR (0.40) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2046531 | 1.00 | PTGIR (0.40) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL1114617 | 1.00 | PTGIR (0.40) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL12571347 | 0.92 | PTGIR (0.49) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2047469 | 0.90 | PDE4D (0.48) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2047466 | 0.90 | PDE4D (0.48) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2047473 | 0.90 | PDE4D (0.48) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2047465 | 0.90 | PDE4D (0.48) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL1111542 | 0.86 | PDE4D (0.42) | PTGIRPTGER2PDE4DKDM4EALDH1A1 | |
| SCHEMBL2053227 | 0.86 | PDE4D (0.42) | PTGIRPTGER2PDE4DKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193373-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7960378-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100063303-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090239930-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2008073752-A2 | CYCLOBUTYL DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239930-A1 | THERAPEUTIC COMPOUNDS | GBA1, ACER2, SLC10A1 | PTGIR 217/4885PTGER2 1580/4885PDE4D 374/4885 |
| US-20100063303-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ABCB1 | PTGIR 618/4885PTGER2 911/4885PDE4D 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.